Retatrutide Phase 2: 24.2% Weight Loss in 48 Weeks
The Phase 2 NEJM trial of retatrutide recorded 24.2% mean weight loss at 48 weeks — the largest reduction ever seen in a Phase 2 peptide trial.
28 May 2026 · 6 min readResearch Blog
Human clinical trial findings, with references to published research.
SURMOUNT-1: Tirzepatide Achieves 22.5% Weight Reduction in 72 Weeks
The SURMOUNT-1 trial in NEJM 2022 showed tirzepatide 15 mg produced 22.5% mean weight loss in 2,539 participants — more than any previously approved weight-loss drug.
21 May 2026 · 6 min readSTEP-1: Semaglutide 2.4 mg and 14.9% Mean Weight Loss in 68 Weeks
The STEP-1 trial in NEJM 2021 established semaglutide 2.4 mg as the first GLP-1 peptide to produce clinically significant weight loss — 14.9% mean reduction in 1,961 participants.
14 May 2026 · 5 min readGLP-1 Peptide Trials: What 5,838 Subjects Tell Us
Three consecutive NEJM trials — STEP-1, SURMOUNT-1, and the retatrutide Phase 2 — enrolled 5,838 subjects and tell a clear story: each generation of GLP-1 peptide meaningfully outperforms the last.
7 May 2026 · 7 min readTesamorelin and Visceral Fat: FDA-Approved Phase 3 Results
Tesamorelin is the only peptide with FDA approval specifically for visceral fat reduction. The pooled Phase 3 analysis of 806 patients showed a 15.4% reduction in visceral adipose tissue at 26 weeks.
30 April 2026 · 5 min readThymosin Beta-4 in Humans: Phase I Safety and Cardiac Repair Data
A Phase I trial in 84 healthy subjects confirmed TB-500's safety and dose-proportional pharmacokinetics. A subsequent cardiac repair trial showed a 67-metre improvement in 6-minute walk distance in acute MI patients.
23 April 2026 · 5 min readGHK-Cu and Collagen: What a Randomised Human Trial Found
A randomised trial in 67 women with moderate facial ageing found that topical GHK-Cu produced collagen increases in 70% of subjects — outperforming tretinoin (40%) over 12 weeks.
16 April 2026 · 4 min readBPC-157: Strong Animal Data, Early Human Safety — Where the Evidence Actually Stands
BPC-157 has a compelling animal literature spanning decades. A 2025 human safety pilot (2 subjects) confirmed IV tolerability. Efficacy trials in humans have not yet been published.
9 April 2026 · 5 min readMelanotan 2: Clinical Evidence for MT-2-Induced Melanogenesis
Two Phase I human trials — Dorr et al. (1996) and Wessells et al. (1998) — confirmed dose-dependent melanogenesis and tanning in human subjects following subcutaneous Melanotan 2 administration.
2 April 2026 · 4 min readWhat Is a Research Peptide? The Pipeline from Lab to Clinic
Research peptides are compounds studied in controlled settings to understand their biological effects. This post explains the development pipeline from preclinical research through Phase I, II, and III trials to regulatory approval.
26 March 2026 · 5 min read